IGM Biosciences Statistics
Total Valuation
IGM Biosciences has a market cap or net worth of $82.06 million. The enterprise value is -$90.87 million.
Important Dates
The next estimated earnings date is Thursday, March 6, 2025, after market close.
| Earnings Date | Mar 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
IGM Biosciences has 59.46 million shares outstanding. The number of shares has increased by 24.54% in one year.
| Current Share Class | 34.08M |
| Shares Outstanding | 59.46M |
| Shares Change (YoY) | +24.54% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | 2.51% |
| Owned by Institutions (%) | 11.16% |
| Float | 10.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 28.51 |
| Forward PS | 7.69 |
| PB Ratio | 1.04 |
| P/TBV Ratio | 1.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.22, with a Debt / Equity ratio of 0.58.
| Current Ratio | 5.22 |
| Quick Ratio | 5.00 |
| Debt / Equity | 0.58 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -132.11% and return on invested capital (ROIC) is -69.34%.
| Return on Equity (ROE) | -132.11% |
| Return on Assets (ROA) | -37.38% |
| Return on Invested Capital (ROIC) | -69.34% |
| Return on Capital Employed (ROCE) | -89.39% |
| Revenue Per Employee | $13,027 |
| Profits Per Employee | -$981,442 |
| Employee Count | 224 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, IGM Biosciences has paid $242,000 in taxes.
| Income Tax | 242,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.42% in the last 52 weeks. The beta is 0.02, so IGM Biosciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.02 |
| 52-Week Price Change | -91.42% |
| 50-Day Moving Average | 3.93 |
| 200-Day Moving Average | 9.31 |
| Relative Strength Index (RSI) | 26.23 |
| Average Volume (20 Days) | 368,014 |
Short Selling Information
The latest short interest is 959,690, so 1.61% of the outstanding shares have been sold short.
| Short Interest | 959,690 |
| Short Previous Month | 1.96M |
| Short % of Shares Out | 1.61% |
| Short % of Float | 9.26% |
| Short Ratio (days to cover) | 1.08 |
Income Statement
In the last 12 months, IGM Biosciences had revenue of $2.92 million and -$219.84 million in losses. Loss per share was -$3.65.
| Revenue | 2.92M |
| Gross Profit | -181.46M |
| Operating Income | -232.89M |
| Pretax Income | -236.33M |
| Net Income | -219.84M |
| EBITDA | -223.95M |
| EBIT | -232.89M |
| Loss Per Share | -$3.65 |
Full Income StatementBalance Sheet
The company has $218.79 million in cash and $45.86 million in debt, giving a net cash position of $172.93 million or $2.91 per share.
| Cash & Cash Equivalents | 218.79M |
| Total Debt | 45.86M |
| Net Cash | 172.93M |
| Net Cash Per Share | $2.91 |
| Equity (Book Value) | 78.95M |
| Book Value Per Share | 1.33 |
| Working Capital | 185.67M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$166.18 million and capital expenditures -$6.44 million, giving a free cash flow of -$172.62 million.
| Operating Cash Flow | -166.18M |
| Capital Expenditures | -6.44M |
| Free Cash Flow | -172.62M |
| FCF Per Share | -$2.90 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -7,981.25% |
| Pretax Margin | -7,525.74% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IGM Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.54% |
| Shareholder Yield | -24.54% |
| Earnings Yield | -267.90% |
| FCF Yield | -210.36% |
Analyst Forecast
The average price target for IGM Biosciences is $6.14, which is 344.93% higher than the current price. The consensus rating is "Hold".
| Price Target | $6.14 |
| Price Target Difference | 344.93% |
| Analyst Consensus | Hold |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 89.52% |
| EPS Growth Forecast (5Y) | -23.44% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
IGM Biosciences has an Altman Z-Score of -4.85 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.85 |
| Piotroski F-Score | 3 |